Global Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Treatment (Medication, Surgery, and Other Therapy), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Gender (Female and Male), End User (Hospitals & Clinics, Specilaty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct, Retail and Online) – Industry Trends and Forecast to 2030.
Stroke Market Analysis and Insights
Stroke is a significant global health concern with thousands of people affected every year and a substantial economic burden on healthcare systems worldwide. The global stroke market includes a wide range of stakeholders, from pharmaceutical companies developing medications for stroke prevention and treatment, medical device manufacturers producing tools for diagnosis and intervention, to rehabilitation and care providers focusing on post-stroke recovery, However, the market faces challenges such as the high cost associated with treatment cost, lack of skilled personnel, and complex regulatory requirements .
The global stroke market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.5% in the forecast period of 2023 to 2030 and is expected to reach USD 52,232,195.85 thousand by 2030 from USD 30,308,643.28 thousand in 2022.
Global stroke market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Thousand
|
Segments Covered
|
Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Treatment (Medication, Surgery, and Other Therapy), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Gender (Female and Male), End User (Hospitals & Clinics, Specilaty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct, Retail and Online)
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East and Africa
|
Market Players Covered
|
Bayer AG, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Medtronic, Teva Pharmaceuticals USA, Inc., Pfizer Inc., AstraZeneca, Viatris Inc., Lupin, Abbott, DAIICHI SANKYO COMPANY, LIMITED, Penumbra, Inc., Oxford Laboratories Pvt. Ltd., Sandoz Group AG (Subsidiary of Novartis AG), GLENMARK PHARMACEUTICALS LTD., Fresenius SE & Co. KGaA, and Amneal Pharmaceuticals LLC, among others.
|
Market Definition
A stroke, encompassing both cardiovascular and brain strokes, is a sudden and severe disruption of blood flow within the circulatory system that results in damage to brain tissue or other vital organs. This interruption in blood supply may be caused by either the blockage of blood vessels (ischemic stroke) or the rupture of blood vessels (haemorrhagic stroke).
Global Stroke Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Incidences of Stroke
In recent years, the world has witnessed a notable surge in the prevalence of stroke, emerging as a significant global health concern. While the incidence of strokes varies by region and is influenced by factors such as age, lifestyle, and healthcare access, the overall trend is one of increasing prevalence.
For instance
• In May 2023, according to the article published by eClinical Medicine, stroke is the second leading cause of death and the third leading cause of disability worldwide. Over the past 30 years, there has been an increase in the absolute number of incidents (70%) and prevalent (85%) strokes, and deaths (43%) from stroke. The increasing use of stroke in genetic studies reflects their unique advantages in the field of genetic research.
In conclusion, factors such as the aging population, unhealthy lifestyles, and increased prevalence of risk factors, all contribute to the growing number of stroke cases. Thus, the rising incidence of stroke is expected to drive market growth.
- Increasing Number of Patients with Hypertension and Coronary Heart Diseases
Hypertension, commonly known as high blood pressure, is a medical condition characterized by elevated force of blood against the walls of arteries. Coronary heart disease also known as coronary artery disease, results from the gradual accumulation of fatty deposits (atherosclerosis) in the coronary arteries, which supply oxygen and nutrients to the heart muscle.
Stroke is intimately connected to the increasing prevalence of hypertension and coronary heart disease (CHD) patients due to shared risk factors and underlying physiological mechanisms. Hypertension, or high blood pressure, significantly raises the risk of stroke by damaging blood vessels and increasing the likelihood of blood clots. Prolonged hypertension can lead to atherosclerosis, and accumulation of fatty deposits in arteries. This can result in narrowed blood vessels and reduced blood flow to the brain, increasing the risk of both ischemic (caused by blockages) and hemorrhagic (caused by bleeding) strokes. High blood pressure can also damage the blood vessels in the brain, making them more prone to rupture or blockage, further escalating the stroke risk.
Opportunity
- Expansion of Telemedicine and Remote Monitoring
The expansion of telemedicine and remote monitoring has been a significant development in stroke treatment and care. These technologies offer numerous advantages, including increased accessibility, rapid assessment, and continuous monitoring, which can significantly improve stroke patients' management and outcomes.
Telemedicine enables patients to have real-time video consultations with healthcare providers, particularly stroke specialists. In the event of a stroke, time is of the essence, and telemedicine allows for immediate assessment and decision-making, reducing delays in treatment. Telemedicine also extends stroke care to underserved and rural areas, where access to stroke specialists may be limited..
These technologies enhance access to specialized stroke care, offer rapid diagnosis helps in making treatment protocol, and facilitate ongoing monitoring and rehabilitation. As a result, healthcare providers can reach a broader patient base, particularly in underserved and remote areas, while streamlining care coordination through stroke networks. The timely provision of stroke expertise and decision support in thrombolytic therapy can improve patient outcomes and reduce the risk of long-term disabilities
Restraint/ Challenge
- High Cost Associated with Treatment of Stroke
The high cost associated with the treatment of stroke is a significant concern in healthcare, impacting both individuals and healthcare systems.
The initial stage of stroke treatment involves emergency medical care, including ambulance services, emergency room evaluations, and diagnostic tests such as CT scans and MRIs. The urgency and complexity of this care drive up costs.
For instance,
- In July 2020, according to an article published by Brand New Vegan LLC, strokes constitute different tests which includes multiple CT scans, an MRI, a slew of other assorted tests and labs, and a semi-private room overnight for further observation, which is estimated a USD 24,000 per person in the U.S.
Complications in Managing Stroke in Patients with Multiple Chronic Conditions
Managing stroke in patients with multiple chronic conditions presents complex challenges, as these coexisting health issues can complicate treatment and recovery.
One of the complications in managing stroke in patients with multiple chronic conditions are;
Polypharmacy and Medication Interactions: Patients with multiple chronic conditions often take multiple medications, which can lead to polypharmacy, increasing the risk of drug interactions and adverse effects. In stroke management, this can complicate medication decisions, especially for anticoagulants or antiplatelet drugs, and make it challenging to balance the risk of bleeding and clotting.
Recent Developments
- In May 2023, Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen), announced that all three potential indications for milvexian, an investigational oral factor XIa (FXIa) inhibitorhas now received fast track designation from the U.S. Food and Drug Administration (FDA). The names include all three trials seeking indications in the Phase 3 Librexiadevelopment program (Librexia STROKE, Librexia ACS, and Librexia AF), all dosed patients. The Librexia program is unparalleled as a comprehensive clinical development program for FXIa, providing extensive data from nearly 50,000 patients. This opens the door to a whole new range of currently neglected patients due to the risk of bleeding.
- In January 2023, Penumbra, Inc., a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration (FDA) approval and launch of Lightning Flash, the most advanced and powerful mechanical thrombectomy system on the market. Lightning Flash features Penumbra's new Lightning Intelligent Aspiration technology, which now has two clot detection algorithms. Combined with innovative catheter technology, the Lightning Flash is designed to quickly remove large blood clots from the body, including venous embolism and pulmonary embolism (PE). This launch will help the company expand its product portfolio because the advanced results of this new technology are exceptionally traceable, and it has the unique ability to differentiate flowing blood from clots.
- In July 2023, Roche announced a new partnership with Alnylam to develop and commercialize zilebesir, an investigational RNAi therapy currently in Phase 2 for treating high blood pressure. This collaboration combines Alnylam's proven experience in RNAi therapy with Roche's global commercial reach, commitment to innovation, and desire to change the landscape for patients with severe cardiovascular disease.
- In February 2021, Sanofi’s Plavix (clopidogrel) got approval by the European Commission for its use in combination with aspirin in adult patients with moderate or high-risk transient ischemic attack (TIA) (ABCD2 score ≥4) or mild ischemic stroke (IS). Twenty-four hours of a TIA or IS event. In this new indication, use can be continued for 21 days, followed by long-term single antiplatelet therapy. The additional indication is based on the results of a two-investigator-initiated, double-blind, randomized, placebo-controlled phase 3 study involving more than 10,000 patients. Studies have shown that the combination of clopidogrel and aspirin started within 24 hours is better than aspirin in reducing the risk of subsequent stroke and has a generally acceptable safety profile. This new approval demonstrates companies unwavering commitment to advancing cardiovascular care.
- In September 2020, Daiichi Sankyo Company Limited announced that it had submitted a supplemental application in Japan for the extended approval of the anticoagulant edoxaban (edoxaban benzoate hydrate) in elderly patients with nonvalvular regurgitation and severe bleeding risk. This application is based on the results of a Japanese Phase 3 clinical trial (ELDERCARE-AF trial) in 984 patients with non-valvular atrial fibrillation who are at least 80 years old and have a high risk of bleeding and are not suitable for other available anticoagulant therapies. Daiichi Sankyo plans to contribute to treating elderly patients with non-valvular atrial fibrillation by offering a new treatment option.
Global Stroke Market Scope
Global stroke market is categorized into five notable segments based on type, treatment, diagnosis, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Ischemic Stroke
- Hemorrhagic Stroke
- Transient Ischemic Attack (TIA)
On the basis of type, the global stroke market is segmented into ischemic stroke, hemorrhagic stroke, and Transient Ischemic Attack (TIA).
Treatment
- Medication
- Surgery
- Others Therapy
On the basis of treatment, the global stroke market is segmented into medication, surgery, and others therapy.
Diagnosis
- Imaging Test
- Blood Test
- Echocardiogram
- Lumbar Puncture
- Others
On the basis of diagnosis, the global stroke market is segmented into imaging test, blood test, echocardiogram, lumbar puncture, and others.
Gender
- Female
- Male
On the basis of gender, the global stroke market is segmented into female and male.
End User
- Hospitals & Clinics
- Specialty Clinics
- Ambulatory Surgical Center
- Homecare
- Laboratories
- Others
On the basis of end-user, the global stroke market is segmented into hospitals & clinics, specialty clinics, ambulatory surgical center, homecare, laboratories, and others.
Distribution Channel
- Direct
- Retail
- Online
On the basis of distribution channel, the global stroke market is segmented into direct, retail, and online.
Global Stroke Market Regional Analysis/Insights
The global stroke market is categorized into six notable segments such as type, treatment, diagnosis, gender, end user, and distribution channel.
The countries covered in this market report U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East and Africa.
North America is expected to dominate the market due to the presence of key market players in the largest consumer market with high GDP. The U.S. dominates North America region due to the rise in technological advancement in the stroke products market. The Germany is expected to dominate the Europe region due to the strong presence of key players. China is expected to dominate the Asia-Pacific region due to the rising incidences of stroke and increasing demand from emerging markets and expansion.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Stroke Market Share Analysis
The global stroke market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the global stroke market.
Some of the major players operating in the global stroke market are Bayer AG, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Medtronic, Teva Pharmaceuticals USA, Inc., Pfizer Inc., AstraZeneca, Viatris Inc., Lupin, Abbott, DAIICHI SANKYO COMPANY, LIMITED, Penumbra, Inc., Oxford Laboratories Pvt. Ltd., Sandoz Group AG (Subsidiary of Novartis AG), GLENMARK PHARMACEUTICALS LTD., Fresenius SE & Co. KGaA, and Amneal Pharmaceuticals LLC, among others.
SKU-